Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
BioMarin Pharmaceutical ( (BMRN) ) has shared an update.
On January 26, 2026, BioMarin Pharmaceutical announced a planned private offering of $850 million in senior unsecured notes due 2034 and the launch of syndication for a new $2 billion senior secured term loan B facility, alongside an existing $800 million term loan A and a new $600 million revolving credit facility, all tied to its pending acquisition of Amicus Therapeutics. The company plans to use proceeds from the notes, the term facilities, and cash on hand to fund the Amicus purchase and related fees, with note proceeds held in escrow and subject to mandatory redemption if the deal is not completed by December 19, 2026; the notes will be guaranteed by key subsidiaries and governed by restrictive covenants, underscoring a significant increase in leverage and a more complex capital structure as BioMarin finances a transformative acquisition in the rare-disease space.
The most recent analyst rating on (BMRN) stock is a Buy with a $98.00 price target. To see the full list of analyst forecasts on BioMarin Pharmaceutical stock, see the BMRN Stock Forecast page.
Spark’s Take on BMRN Stock
According to Spark, TipRanks’ AI Analyst, BMRN is a Outperform.
The score is driven primarily by strong financial performance (high margins, improved profitability, robust cash generation, and low leverage) and a supportive technical uptrend (price above major moving averages with positive MACD). Guidance and VOXZOGO momentum add support, while a moderate valuation (P/E ~22.9 with no dividend yield provided) and notable earnings-call lowlights (IPR&D charge and portfolio uncertainty around ROCTAVIAN) temper the upside.
To see Spark’s full report on BMRN stock, click here.
More about BioMarin Pharmaceutical
BioMarin Pharmaceutical is a global biotechnology company specializing in therapies for rare, genetically defined diseases. Founded in 1997 and based in San Rafael, California, it markets eight commercial therapies and maintains a broad clinical and preclinical pipeline targeting niche patient populations through advanced genetic science.
Average Trading Volume: 2,942,483
Technical Sentiment Signal: Sell
Current Market Cap: $10.8B
See more insights into BMRN stock on TipRanks’ Stock Analysis page.